ARMP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ARMP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Armata Pharmaceuticals's Net-Net Working Capital for the quarter that ended in Mar. 2024 was $-3.85.
The industry rank for Armata Pharmaceuticals's Net-Net Working Capital or its related term are showing as below:
The historical data trend for Armata Pharmaceuticals's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Armata Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Net-Net Working Capital | Get a 7-Day Free Trial | -0.49 | -0.59 | -1.26 | -1.24 | -3.24 |
Armata Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Net-Net Working Capital | Get a 7-Day Free Trial | -1.69 | -1.93 | -2.80 | -3.24 | -3.85 |
For the Biotechnology subindustry, Armata Pharmaceuticals's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Armata Pharmaceuticals's Price-to-Net-Net-Working-Capital falls into.
Armata Pharmaceuticals's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as
Net-Net Working Capital | (A: Dec. 2023 ) | ||||||
= | (Cash, Cash Equivalents, Marketable Securities | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (13.523 | + | 0.75 * 0 | + | 0.5 * 0 | - | 130.428 |
- | 0 | - | 0) | / | 36.1229 | ||
= | -3.24 |
Armata Pharmaceuticals's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as
Net-Net Working Capital | (Q: Mar. 2024 ) | ||||||
= | (Cash, Cash Equivalents, Marketable Securities | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (37.86 | + | 0.75 * 0 | + | 0.5 * 0 | - | 176.866 |
- | 0 | - | 0) | / | 36.1321 | ||
= | -3.85 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
Armata Pharmaceuticals (AMEX:ARMP) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Thank you for viewing the detailed overview of Armata Pharmaceuticals's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard Rychlik | officer: Corporate Controller and PFO | 5005 MCCONNELL AVENUE, LOS ANGELES CA 90066 |
Deborah Birx | director, officer: Chief Executive Officer | 3300 LOWELL STREET NW, WASHINGTON DC 20008 |
Julianne Averill | officer: Chief Financial Officer | 361 NEWBURY STREET, SUITE 500, BOSTON MA 02115 |
Erin Butler | officer: Vice President,Finance & Admin | 4375 LOMA RIVIERA COURT, SAN DIEGO CA 92110 |
Theravance Inc | director, 10 percent owner | 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010 |
Jules Haimovitz | director | 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004 |
Innoviva Strategic Opportunities Llc | director, 10 percent owner | 1209 ORANGE STREET, WILMINGTON DE 19801 |
Robin Kramer | director | 999 VANDERBILT BEACH ROAD, 3RD FLOOR, NAPLES FL 34109 |
Steven Robert Martin | officer: Chief Financial Officer | 11011 NORTH TORREY PINES ROAD, LA JOLLA CA 92037 |
Kostas D Odysseas | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Sarah J. Schlesinger | director | C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Jeremy Curnock Cook | director | TARGETED GENETICS CORP, 1100 OLIVE WAY STE 100, SEATTLE WA 98101 |
Michael S Perry | director | C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155 |
Todd C. Peterson | director | C/O ARMATA PHARMACEUTICALS, INC., 4503 GLENCOE AVENUE, MARINA DEL REY CA 90292 |
H Stewart Parker | director |
From GuruFocus
By PRNewswire PRNewswire • 05-31-2023
By PRNewswire PRNewswire • 06-12-2022
By PRNewswire • 11-14-2023
By PRNewswire PRNewswire • 12-22-2022
By PRNewswire PRNewswire • 06-21-2022
By PRNewswire • 07-11-2023
By PRNewswire PRNewswire • 06-01-2022
By PRNewswire PRNewswire • 08-11-2022
By PRNewswire PRNewswire • 05-12-2022
By PRNewswire PRNewswire • 06-22-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.